Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
10.0
5.5
Journals
Pharmaceutics
Special Issues
Advances in Nanoparticle-Driven Approaches for Targeted Brain Drug Delivery
share announcement

Advances in Nanoparticle-Driven Approaches for Targeted Brain Drug Delivery

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Nanomedicine and Nanotechnology".

Deadline for manuscript submissions: 31 December 2025 | Viewed by 620

Special Issue Editors

Prof. Dr. Snezana Savic

E-Mail Website
Guest Editor
Department of Pharmaceutical Technology and Cosmetology, Faculty of Pharmacy, University of Belgrade, Vojvode Stepe 450, 11221 Belgrade, Serbia
Interests: nanoplatforms for brain and skin delivery; innovative biocompatible excipients; poorly water-soluble drugs; physicochemical/in vitro/in silico characterization methods; in vivo pharmacokinetics in rats
Special Issues, Collections and Topics in MDPI journals
Dr. Tanja Ilić

E-Mail Website
Guest Editor
Department of Pharmaceutical Technology and Cosmetology, Faculty of Pharmacy, University of Belgrade, Vojvode Stepe 450, 11221 Belgrade, Serbia
Interests: lipid nanoplatforms for localized drug delivery (brain, skin); formulation development; physicochemical characterization methods; in vitro drug permeation through biological barriers (blood–brain barrier, skin); in vivo (dermo) pharmacokinetics
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Despite the substantial progress achieved in neuroscience and neuropharmacology, the effective treatment of various central nervous system disorders remains a challenge. The blood–brain barrier (BBB), together with the blood–cerebrospinal fluid barrier, protects and regulates the homeostasis of the brain and thus limits the access of most drugs. To deliver a sufficient therapeutic concentration of a drug to the intended site of action in the brain in a predictable/controlled manner, various nanoparticle-based drug delivery systems have been proposed, such as ligand-functionalized or stimuli-responsive nanocarriers, often in combination with transient BBB disruption (e.g., focused ultrasound waves, osmotic agents) or alternative delivery routes (e.g., intranasal route, meningeal lymphatic reverse pathway). Therefore, this Special Issue aims to collect recent developments and challenges related to various nanoparticle-driven strategies for overcoming the BBB, thus contributing to the creation of new avenues for the successful treatment of brain disorders. We welcome original research articles covering a wide range of topics related to the following areas, among others: novel nanoparticle designs and combinational strategies for targeted brain drug delivery, in vitro/in vivo fate and interactions with the biological environment, biocompatibility and safety assessments, translational research and regulatory perspectives.

We look forward to receiving your contributions.

Prof. Dr. Snezana Savic
Dr. Tanja Ilić
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • brain-related disorders
  • nanotechnology
  • multifunctional nanoparticles
  • targeted drug delivery
  • receptor-mediated transport
  • carrier-mediated transport
  • nose-to-brain delivery
  • meningeal lymphatic reverse pathway
  • blood–brain barrier disruption

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

20 pages, 1920 KB  
Article
3D-Printed Oral Disintegrating Films of Brain-Targeted Acetyl Salicylic Acid Nanoparticles for Enhanced CNS Delivery in Ischemic Stroke
by Dedeepya Pasupuleti, Marissa D’Souza, Amarae Ferguson, Mahek Anil Gulani, Parth Patel, Revanth Singh, Emmanuel Adediran, Sharon Vijayanand, Tanisha Manoj Arte and Martin D’Souza
Pharmaceutics 2025, 17(12), 1547; https://doi.org/10.3390/pharmaceutics17121547 - 30 Nov 2025
Cited by 1 | Viewed by 470
Abstract
Background/Objectives: Oral administration remains the most widely used route for drug delivery but is unsuitable for many central nervous system (CNS) therapeutics due to extensive hepatic first-pass metabolism and the restrictive blood–brain barrier (BBB). Acetyl salicylic acid (ASA), despite its neuroprotective and [...] Read more.
Background/Objectives: Oral administration remains the most widely used route for drug delivery but is unsuitable for many central nervous system (CNS) therapeutics due to extensive hepatic first-pass metabolism and the restrictive blood–brain barrier (BBB). Acetyl salicylic acid (ASA), despite its neuroprotective and anti-inflammatory potential, exhibits poor brain bioavailability when delivered orally, limiting its therapeutic utility in ischemic stroke and chronic neurodegenerative conditions. Methods: This study reports the first use of three-dimensional (3D) bioprinting to develop brain-targeting ASA nanoparticle (NP)-loaded orally disintegrating films (ODFs) for direct systemic uptake and enhanced CNS delivery. The ODFs were fabricated using a CELLINK INKREDIBLE plus® bioprinter and optimized for uniformity, rapid dissolution, and nanoparticle stability. Results: The films displayed consistent physicochemical properties (weight 10.86 ± 0.28 mg; thickness 0.47 ± 0.26 mm; pH 7.5–7.7) and disintegrated within 2.38 ± 0.28 min. In vitro testing on BEND3 brain endothelial cells confirmed biocompatibility, with no inflammatory response or cytotoxicity up to 62 µg/mL. In vivo biodistribution in murine models demonstrated substantial brain accumulation, achieving 14.15 ng/mg tissue following buccal administration. Conclusions: This work establishes a novel, non-invasive CNS drug delivery platform combining 3D bioprinting with ligand-functionalized ASA NPs to bypass hepatic metabolism and improve brain targeting. The rapid-dissolving ODFs demonstrated high reproducibility, safety, and effective brain deposition, highlighting their translational potential for neurological therapeutics. This approach may be extended to other small molecules with limited CNS penetration, offering a versatile pathway toward precision neuropharmacology. Full article
(This article belongs to the Special Issue Advances in Nanoparticle-Driven Approaches for Targeted Brain Drug Delivery)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop